Displaying drugs 651 - 675 of 8388 in total
Lesinurad
Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with...
Approved
Investigational
Matched Description: … Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia ... Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of ... It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake …
Durlobactam
Durlobactam is a diazabicyclooctane non-beta-lactam, beta-lactamase inhibitor. It is typically given in combination with sulbactam to protect it from degradation by certain serine-beta-lactamases. The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023. It is used to treat hospital-acquired bacterial pneumonia and ventilator-associated bacterial...
Approved
Investigational
Matched Description: … [L47336] The combination product of durlobactam and sulbactam was first approved by the FDA in May 2023 ... pneumonia and ventilator-associated bacterial pneumonia (HABP/VABP), caused by susceptible isolates of …
Tenoxicam
Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
Approved
Setmelanotide
Setmelanotide is the first available treatment for patients with pro-opiomelanocortin, proprotein subilisin/kexin type 1, or leptin deficiencies. It is an agonist of the melanocortin 4 receptor. Earlier attempts at agonizing MC4R (such as LY2112688) lead to successful weight loss, but also an increase in blood pressure and heart rate. Other...
Approved
Investigational
Matched Description: … [L24474] It is an agonist of the melanocortin 4 receptor. ... [A224449] Patients taking setmelanotide experienced an average weight loss of 0.6 kg/week. …
Eculizumab
Eculizumab is a monoclonal antibody that targets complement protein C5.[L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which is used to treat a number of autoimmune conditions.[L6919,A2245,A2246]
Eculizumab was granted FDA approval on 16 March 2007. In Q1 2023, the EMA's Committee for Medicinal Products...
Approved
Investigational
Matched Description: … two formulations of eculizumab indicated for the treatment of paroxysmal nocturnal hemoglobinuria. ... is used to treat a number of autoimmune conditions. ... [L6919,A2245] Binding to this protein prevents the activation of a complement terminal complex, which …
Labetalol
Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730]
Labetalol was granted FDA approval on 1 August 1984.
Approved
Matched Description: … 25% of the mixture. ... Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up …
Ubrogepant
Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. It was approved by the FDA on December 23, 2019, and is the first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of migraine. Several oral small molecule CGRP receptor...
Approved
Investigational
Matched Description: … advance in migraine headache treatment and may become the new standard of therapy in the treatment of ... Ubrogepant is indicated for the acute treatment of migraine headaches with or without aura in adults. ... first oral calcitonin gene-related peptide (CGRP) receptor antagonist approved for the acute treatment of …
Methylphenidate
Methylphenidate is a central nervous system stimulant used most commonly in the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) and for narcolepsy. Also known as the marketed products Ritalin, Concerta, or Biphentin, methylphenidate is used with other treatment modalities (psychological, educational, cognitive behaviour therapy, etc) to improve the following group of developmentally...
Approved
Investigational
Matched Description: … [L6037] CADDRA recommends the use of methylphenidate due to long term studies, of over twenty years in ... Within an aqueous environment, such as the stomach, the drug overcoat, which consists of 22% of the dose ... methylphenidate, suggesting a possible mode of action. …
Imatinib
Imatinib is a small molecule kinase inhibitor that revolutionized the treatment of cancer, particularly chronic myeloid leukemia, in 2001. It was deemed a "miracle drug" due to its clinical success, as oncologist Dr. Brian noted that "complete hematologic responses were observed in 53 of 54 patients with CML treated with...
Approved
Matched Description: … with a daily dosage of 300 mg or more and typically occurred in the first four weeks of therapy". ... The discovery of imatinib also established a new group of therapy called "targeted therapy", since treatment ... can be tailored specifically to the unique cancer genetics of each patient. …
Ropivacaine
Ropivacaine is an aminoamide local anesthetic drug marketed by AstraZeneca under the trade name Naropin. It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the purified S-enantiomer.
Approved
Matched Description: … It exists as a racemate of its S- and R-enantiomers, although the marketed form is supplied only as the …
Lumiracoxib
Lumiracoxib is a COX-2 selective non-steroidal anti-inflammatory drug (NSAID). On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver failure. New Zealand and Canada have also followed suit in recalling...
Approved
Investigational
Matched Description: … On August 11, 2007, Australia's Therapeutic Goods Administration (TGA, the Australian equivalent of the ... FDA) cancelled the registration of lumiracoxib in Australia due to concerns that it may cause liver …
Thyroid, porcine
Thyroid extract is dried and powdered thyroid glands from pigs containing tiiodothyronine (T3) and thyroxine (T4) used to supplement low or absent thyroid activity.[A190831,L11755] Thyroid extract has been described in literature to treat hypothyroidism since 1891 but its use dates back as far as the 6th century. Thyroid extract is...
Approved
Matched Description: … considered a first line therapy as it delivers a dose that is inconsistent with the stated strength of …
Isoprenaline
Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160]
Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising...
Approved
Investigational
Matched Description: … [A15638,L33160]
Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine …
Chlorhexidine
Chlorhexidine is a broad-spectrum antimicrobial biguanide used as a topical antiseptic and in dental practice for the treatment of inflammatory dental conditions caused by microorganisms. It is one of the most common skin and mucous membrane antiseptic agents in use today. The molecule itself is a cationic bis-guanide consisting of...
Approved
Vet approved
Withdrawn
Matched Description: … of this product. ... [L43942,L44027] Other formulations of chlorhexidine continue to be available. ... [L11512] It is one of the most common skin and mucous membrane antiseptic agents in use today. …
Ocriplasmin
Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced by recombinant DNA technology in a Pichia pastoris expression system. Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. Agent for pharmacologic vitreolysis; thrombolytic agent. FDA approved...
Approved
Matched Description: … Ocriplasmin is a recombinant truncated form of human plasmin with a molecular weight of 27.2 kDa produced ... Ocriplasmin is a protein made up of 249 amino acids and has two peptide chains. …
Boric acid
Boric acid, also known as hydrogen borate, is a weak monobasic Lewis acid of boron with the chemical formula H3BO3. Boric acid is typically utilized in industrial processing and manufacturing, but is also used as an additive in pharmaceutical products, cosmetics, lotions, soaps, mouthwash, toothpaste, astringents, and eyewashes . It...
Approved
Matched Description: … Boric acid, also known as hydrogen borate, is a weak monobasic Lewis acid of boron with the chemical …
Sodium borate
Approved
Experimental
Busulfan
Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), but although symptomatic relief is provided, no permanent remission is brought...
Approved
Investigational
Matched Description: … It is not a structural analog of the nitrogen mustards. ... It has been used in the palliative treatment of chronic myeloid leukemia (myeloid leukemia, chronic), …
Migalastat
Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substrate that, when deficient in patients with Fabry disease, builds up in the blood vessels, the kidneys,...
Approved
Investigational
Matched Description: … [L4274]
Given the rarity of Fabry disease and the proportion of Fabry disease patients that could ... alpha-Gal A for the treatment of Fabry disease in adults who have amenable GLA variants. ... sold under Amicus Therapeutics' brand name Galafold) is subsequently an oral pharmacological chaperone of …
Disulfiram
A carbamate derivative used as an alcohol deterrent. It is a relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of alcohol. When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased, followed by flushing, systemic vasodilation, respiratory difficulties, nausea, hypotension, and other symptoms...
Approved
Matched Description: … relatively nontoxic substance when administered alone, but markedly alters the intermediary metabolism of ... When alcohol is ingested after administration of disulfiram, blood acetaldehyde concentrations are increased …
Golodirsen
Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular Dystrophy (DMD). This is an X-linked condition leading to progressive muscle degeneration that begins in early childhood, rendering many patients wheelchair-bound by age 12. Often, patients succumb to this condition by age 30 or...
Approved
Matched Description: … [A188580,T756] A similar drug used in the treatment of other types of DMD is [eteplirsen], which targets ... Continued approval of this drug will depend on the results of clinical trials that confirm its clinical ... Golodirsen is a morpholino antisense oligomer designed to treat about 8% of patients with Duchenne Muscular …
Capsaicin
Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, and patch preparations of various strengths; however, it may also be found in some dietary supplements. Capsaicin is a naturally-occurring botanical irritant in chili peppers, synthetically derived for pharmaceutical formulations. The most recent...
Approved
Matched Description: … Capsaicin is most often used as a topical analgesic and exists in many formulations of cream, liquid, ... and patch preparations of various strengths; however, it may also be found in some dietary supplements …
Naldemedine
Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of DB00704 to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and...
Approved
Investigational
Matched Description: … It is a modified form of [DB00704] to which a side chain has been added to increase molecular weight ... Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation …
Paromomycin
An oligosaccharide antibiotic produced by various streptomyces. [PubChem]
Approved
Investigational
Bisoxatin
Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions in the intestine . It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and for preparation of the colon for surgical procedures.
Approved
Matched Description: … for preparation of the colon for surgical procedures. ... Bisoxatin is a stimulant laxative which increases peristalsis and inhibits absorbtion of water and ions ... It is marketed in Belgium under the tradename Wylaxine and used for the treatment of constipation and …
Displaying drugs 651 - 675 of 8388 in total